Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
All previous clinical trials of CAN-2409 in prostate cancer have been published. The key data slides relevant to the current randomized clinical trials that have been reviewed with the FDA and underpin the SPA are in the corporate deck. See also:
- Herman JR et al. Hum Gene Ther…
Thank you @ideapharma !
Candel Therapeutics develops investigational off the shelf medicines that result in an individualized anti-tumor immune response through in situ vaccination.
The legacy company Advantagene initially ran the phase 3 clinical trial of CAN-2409 in intermediate-to-high risk localized prostate cancer conducted under an SPA as a semi-academic enterprise with grant funding only.
In 2017/2018 for the first time professional investors came on…
